Abstract & Authors:展开
Background: Here we report follow-up data from a double-blind, randomized, controlled multicenter trial, which investigated fecal microbiota changes with a new amino acid-based formula (AAF) including synbiotics in infants with non-immunoglobulin E (IgE)-mediated cow's milk allergy (CMA).
Methods: Subjects were randomized to receive test product (AAF including fructo-oligosaccharides and M-16V) or control product (AAF) for 8 weeks, after which infants could continue study product until 26 weeks. Fecal percentages of bifidobacteria and / group () were assessed at 0, 8, 12, and 26 weeks. Additional endpoints included stool markers of gut immune status, clinical symptoms, and safety assessments including adverse events and medication use.
Results: The trial included 35 test subjects, 36 controls, and 51 in the healthy reference group. Study product was continued by 86% and 92% of test and control subjects between week 8-12, and by 71% and 80%, respectively until week 26. At week 26 median percentages of bifidobacteria were significantly higher in test than control [47.0% vs. 11.8% ( < 0.001)], whereas percentages of were significantly lower [(13.7% vs. 23.6% ( = 0.003)]. Safety parameters were similar between groups. Interestingly use of dermatological medication and reported ear infections were lower in test versus control, = 0.019 and 0.011, respectively. Baseline clinical symptoms and stool markers were mild (but persistent) and low, respectively. Symptoms reduced towards lowest score in both groups.
Conclusion: Beneficial effects of this AAF including specific synbiotics on microbiota composition were observed over 26 weeks, and shown suitable for dietary management of infants with non-IgE-mediated CMA. NTR3979.
Adam T Fox,Harm Wopereis
Marleen T J Van Ampting
Adam T Fox,Harm Wopereis,Marleen T J Van Ampting,Manon M Oude Nijhuis,Assad M Butt,Diego G Peroni,Yvan Vandenplas,David C A Candy,Neil Shah,Christina E West,Johan Garssen,Lucien F Harthoorn,Jan Knol,Louise J Michaelis